A Phase 1, Randomized, Single-Blind, Placebo Controlled Study to Assess Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Abediterol (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 24 Nov 2017 Status changed from not yet recruiting to completed.
- 13 Sep 2017 Planned End Date changed from 25 Oct 2017 to 24 Nov 2017.
- 13 Sep 2017 Planned primary completion date changed from 25 Oct 2017 to 24 Nov 2017.